KIMS
KRISHNA INST OF MED SCI L
Each stock's 10,000-path forecast, rendered as light.
KRISHNA INST OF MED SCI L (KIMS) Stock Analysis & Case Study
Is KIMS a good buy? The data-driven verdict.
KRISHNA INST OF MED SCI L (KIMS) trades at ₹806,on the numbers it tread carefully, a Downstox Snapshot Score of 33/100.
On the numbers, KRISHNA INST OF MED SCI L (KIMS) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 130.0× earnings, ROE of 11.3%, a 83% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
KIMS fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is KIMS overvalued? KIMS P/E vs its sector
KIMS's P/E of 130.0× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers.
KIMS share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of KIMS history (34%/yr drift, 31%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| KIMS 2027 | ₹722 | ₹1,081 | ₹1,594 | +34% |
| KIMS 2028 | ₹819 | ₹1,441 | ₹2,544 | +79% |
| KIMS 2029 | ₹979 | ₹1,929 | ₹3,887 | +140% |
| KIMS 2030 | ₹1,174 | ₹2,579 | ₹5,778 | +221% |
| KIMS 2031 | ₹1,435 | ₹3,459 | ₹8,358 | +330% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability KIMS goes up, or doubles?
The bull case for KIMS
- A 10,000-path probability model puts a 83% chance the price is higher in a year, with a median target of ₹1,081 (+34%).
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹3,887.
The bear case & risks
- A rich 130.0× P/E leaves a thin margin of safety if growth slows.
- A steep 14.3× price-to-book means most of the value is intangible/expectations, not assets on the books.
- Return on equity is a soft 11.3%, capital efficiency trails higher-quality peers.
- A low Piotroski F-Score of 3/9 flags weaker financial health this cycle, worth understanding why before committing.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹979.
KIMS volatility & expected range, how bumpy is the ride?
Over the last 2.0 years KIMS compounded at 34%/year with annualized volatility of 31%. That volatility implies a 1-year 80% range of ₹722–₹1,594, the honest backbone behind any single price target.
KIMS price forecast, the full 60-month probability fan
KIMS price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds KIMS hits common targets within the simulated horizon?
Full multi-horizon detail on the KIMS price target & forecast page.
KIMS Piotroski F-Score: 3/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. KIMS scores 3/9,weak on the financial-strength checks.
KIMS MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy KIMS with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| UpstoxCHEAPEST | 30.8% | 3.2× |
| ZerodhaCHEAPEST | 30.8% | 3.2× |
| DhanCHEAPEST | 30.8% | 3.2× |
Compare every broker on the KIMS MTF page.
KIMS vs peers,sector comparison
About KRISHNA INST OF MED SCI L: sector, index & market-cap context
KRISHNA INST OF MED SCI L (KIMS) is a mid-cap NSE-listed company, and a constituent of the Nifty 100 index group, with a market capitalisation of ₹32,241 Cr. See more Nifty 100 stocks.
How the KIMS Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of KRISHNA INST OF MED SCI L's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
KIMS analysis, FAQs
Is KRISHNA INST OF MED SCI L (KIMS) a good buy?
On the numbers, KRISHNA INST OF MED SCI L (KIMS) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 130.0× earnings, ROE of 11.3%, a 83% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is KIMS overvalued or undervalued?
KIMS trades at 130.0× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the KIMS share price target for 2031?
KIMS's probability-weighted 2031 median target is ₹3,459, with an 80% range of ₹1,435–₹8,358 (10,000-path Monte-Carlo).
What is the probability KIMS doubles in 5 years?
The modelled probability of KIMS reaching ₹1,609 (2×) within 5 years is 86%.
What is the bull case for KIMS?
A 10,000-path probability model puts a 83% chance the price is higher in a year, with a median target of ₹1,081 (+34%).
What are the risks in KIMS?
A rich 130.0× P/E leaves a thin margin of safety if growth slows. A steep 14.3× price-to-book means most of the value is intangible/expectations, not assets on the books. Return on equity is a soft 11.3%, capital efficiency trails higher-quality peers.